abrdn plc Raises Holdings in Pfizer Inc. (NYSE:PFE)

abrdn plc lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 108.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,469,299 shares of the biopharmaceutical company's stock after purchasing an additional 2,321,671 shares during the quarter. abrdn plc owned about 0.08% of Pfizer worth $128,671,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Worth Asset Management LLC purchased a new stake in shares of Pfizer in the first quarter worth $29,000. Briaud Financial Planning Inc bought a new position in shares of Pfizer in the third quarter worth approximately $30,000. GoalVest Advisory LLC grew its holdings in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. purchased a new position in Pfizer in the 3rd quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC boosted its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.61 during midday trading on Friday, reaching $26.00. 38,372,801 shares of the stock traded hands, compared to its average volume of 34,236,664. The company's 50 day moving average is $27.11 and its 200 day moving average is $28.65. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a market capitalization of $147.23 billion, a PE ratio of 72.22, a P/E/G ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the company earned $1.14 EPS. The company's revenue for the quarter was down 41.3% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on PFE shares. Argus downgraded Pfizer from a "buy" rating to a "hold" rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. TD Cowen lowered Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a "buy" rating and a $36.00 price target on the stock. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.